PSIQI

Analytical science & research infrastructure

Measured
medicine
starts here.

PSIQI is developing a laboratory platform through acquisition, with a focus on analytical science.

Pre-acquisition thesis Colorado focus

Illustrative optical glass and precisely refracted light on a dark laboratory surface
Precision is the starting point.Conceptual scientific imagery

A platform built on evidence.

Existing operationsScientific disciplineMeasured expansion

The starting point

Acquire a foundation.
Build with discipline.

Begin with the people, relationships and operating systems of an established laboratory. Earn the right to expand through reliable work and demonstrated demand.

Acquire

A laboratory with substance.

Target a business with repeat customers, strong scientific leadership, defensible records and sound underlying economics.

Strengthen

Quality that compounds.

Invest in methods, documentation and service delivery. Preserve the expertise that makes the laboratory valuable.

Expand

One proven step at a time.

Evaluate specialized research services when customers, capability and the regulatory pathway support the investment.

Illustrative close-up of a gloved scientist handling a sample vial beside analytical instrumentation
Illustrative laboratory detail · AI-generated

The operating philosophy

Trust lives
in the details.

Useful science depends on more than an instrument. It depends on the method, the record, the person reviewing the result, and the consistency of the work.

That is the operating foundation PSIQI aims to build.

Explore the business model

The proposed path

Progress, with
proof at every stage.

Each expansion is a separate decision.
Every decision needs evidence.

Initial acquisition thesis

Start with an operating business.

Retain existing customers, scientific talent and quality systems. Underwrite the acquisition on verified operating economics.

Decision evidenceTarget diligence · normalized cash flow · key staff retention · legal fit

Research notes

A changing field.
A grounded perspective.

Read the source notes

Regulatory context · July 2026

FDA guidance moves from draft to final.

A more current foundation for discussing clinical development and its requirements.

Read context

Clinical development · November 2026

A leading program reaches NDA submission.

Compass reported its COMP360 submission. The distinction between submission and approval still matters.

Read context

Build the foundation with us

Good science starts
with a conversation.

For investors, laboratory owners and scientific partners.

info@psiqi.com